Nivolumab for the Treatment of Metastatic or Unresectable Solid Tumors With ARID1A Mutation and CXCL13 Expression

Clinical trial NCT04957615 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT04957615
Sponsor: M.D. Anderson Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Metastatic Malignant Solid Neoplasm Unresectable Solid Neoplasm

Start date: 2021-09-21
Primary completion: 2027-05-31
Enrollment: 16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.